The lawsuit, pending in the U.S. District Court for the District of Connecticut under the name Basma v. GeneDx Holdings Corp., alleges the company and its executives misled shareholders regarding the performance and integration of its business lines. Tensions peaked on May 4, 2026, when the company revealed that adjusted gross margins had slipped from 74% to 69%. Alongside the margin contraction, GeneDx missed revenue estimates for its exome and genome product lines and slashed its full-year revenue guidance from a range of $540–$550 million down to $475–$490 million.
In section Releases
Investors Face August Deadline in GeneDx Securities Class Action
Investors who purchased GeneDx Holdings Corp. stock between April 2025 and May 2026 have until August 3, 2026, to file as lead plaintiffs in a securities fraud lawsuit. The litigation follows a sharp 49% share price collapse sparked by missed revenue targets and a significant impairment charge linked to a corporate acquisition.
Financial strain was further highlighted by a $31.2 million impairment loss tied to the acquisition of Fabric Genomics. While GeneDx previously promoted the AI-driven firm as a transformative engine for recurring revenue, the reality of the integration proved costly. Following these disclosures, the company's stock price plummeted by $33.42, effectively wiping out nearly half of its market value in a single session. Kahn Swick & Foti, LLC is currently representing investors seeking to recover losses associated with these claims.
Comments (0)
No comments yet. Be the first!